Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Transplantation Proceedings

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.transproceed.2016.03.005PMID 27496459
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proteinuria associated with mTOR inhibitors after kidney transplant.

  2014cited by this paper
• Association of a change in immunosuppressive regimen with hemodynamic and inflammatory markers of cardiovascular disease after kidney transplantation.

  2013cited by this paper
• Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial

  2013cited by this paper
• Immunosuppressant Regimen Based on Sirolimus Decreases Aortic Stiffness in Renal Transplant Recipients in Comparison to Cyclosporine

  2011cited by this paper
• Lower homocysteine levels in renal transplant recipients treated with everolimus: a possible link with a decreased cardiovascular risk?

  2010cited by this paper
• Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients

  2008cited by this paper
• Diabetes after transplantation and sirolimus: what's the connection?

  2008cited by this paper
• Sirolimus-eluting stents suppress neointimal formation irrespective of metallic allergy.

  2008cited by this paper
• Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients.

  2008cited by this paper
• Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells.

  2007cited by this paper
• Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.

  2005cited by this paper
• Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation.

  2003cited by this paper
• Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine–based immunosuppressive regimen: incidence, risk factors, progression, and prognosis1

  2003cited by this paper
• Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patients. A new model for the quantitation and follow-up of preclinical atherosclerosis in living human subjects.

  1988cited by this paper

• Long-term Effects of Kidney Transplantation Compared With Dialysis on Intima–media Thickness in Children—Results From the 4C-T Study

  2024cites this paper
• Potential Effects of Immunosuppression on Oxidative Stress and Atherosclerosis in Kidney Transplant Recipients

  2021influential citation
• Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures

  2021cites this paper
• Progression of endothelial dysfunction, atherosclerosis, and arterial stiffness in stable kidney transplant patients: a pilot study

  2019cites this paper
• Effect of sirolimus on carotid atherosclerosis in kidney transplant recipients: data derived from a prospective randomized controlled trial

  2018cites this paper
• Improving long‐term outcomes after pediatric renal transplantation by addressing dyslipidemia

  2017cites this paper